Tiny trial hopes drug can ease liver damage in rare triple condition

NCT ID NCT06144086

Completed Disease control Sponsor: Kiminori Kimura, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 2 trial tested a drug called foscenvivint in just 5 people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. The goal was to see if the drug could improve liver function scores over 24 weeks. Because the study is very small and early, the results are uncertain but may guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: foscenvivint (a drug given by IV infusion)
What this could lead to: If it works, this could point toward a treatment to improve liver function in people with cirrhosis from HIV/HCV co-infection and hemophilia.
What could go wrong: This is a very small, early-phase trial with only 5 participants, so results may not apply to others. The drug may not improve liver function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS

Contacts and locations

Locations

Hokkaido University Hospital

Sapporo, Hokkaido, 060-8648, Japan
National Hospital Organization Osaka National Hospital

Osaka, Osaka, 540-0006, Japan
Tokyo Metropolitan Komagome Hospital

Bunkyo-Ku, Tokyo, 113-8677, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.